Visterra raises $30m for infectious disease pipeline
This article was originally published in Scrip
Visterra raised a $30m Series B round from new and existing venture capital investors to fund clinical development of the company's pipeline of novel monoclonal antibodies to prevent and treat infectious diseases.
You may also be interested in...
AnaptysBio, Jounce and ObsEva were the first three companies to go public in 2017 – all in January – while no therapeutics firms went public in January 2016. The difference? Better US biopharma stock performance.
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.